Rhythm

Kardium® announces successful results from the GLOBAL-AF study

VANCOUVER, British Columbia–(BUSINESS WIRE)–Kardium Inc. today announced that the Globe® mapping and ablation system has successfully demonstrated safety and efficacy in the GLOBAL-AF study. The results of the study were published in the Journal of Cardiovascular Electrophysiology. The study demonstrated a 76% percent freedom from atrial fibrillation at 12 months after a […]

Medtronic Initiates Worldwide Pivotal Study of a New Approach to Treating Dangerously Fast Heart Rhythms

Study to Evaluate Novel Implantable Defibrillator System with a Lead Placed Outside the Heart and Veins DUBLIN, Oct. 07, 2019 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT) today announced the start of a worldwide pivotal study evaluating its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system to treat dangerously fast heart rhythms. The […]

Preventice Solutions Receives Tender from UK Biobank for 3-Year, 30,000-Participant Cardiovascular Monitoring Study

MINNEAPOLIS, Oct. 2, 2019 /PRNewswire/ — Preventice Solutions announced today it received a tender from the UK Biobank to provide the BodyGuardian® MINI remote cardiac monitor for a cardiovascular monitoring study involving up to 30,000 participants.  The study is designed to capture data on asymptomatic heart rhythm disturbances (arrhythmia), including atrial fibrillation (AF), […]

AdjuCor Announces First Successful In Vivo 60-Day Pre-Clinical Survival Study using its Cutting-edge Non-blood-contacting, Biventricular Cardiac Support Device.

After completing a 60-day pre-clinical study, Professor Stephen Wildhirt, MD, PhD, CEO at AdjuCor, is excited to report on its success. Apart from other achievements, the study confirmed the chronic physiologic acceptance of their non-blood-contacting biventricular cardiac support device by the body. AdjuCor has previously completed a successful 30-day in vivo study. […]

Orchestra BioMed Announces Late-Breaking Clinical Results Showing BackBeat Cardiac Neuromodulation Therapy™ Drives Significant Reduction in Systolic Blood Pressure

Double-blind, randomized trial data demonstrates clinically meaningful and statistically significant difference of 8.1 mmHg in reduction of 24-hour ambulatory systolic blood pressure at 6 months vs. control High responder rate despite 88.5% of treated patients having isolated systolic hypertension (ISH) Primary safety endpoint achieved with no difference in major cardiac […]

Fitbit and FibriCheck Announce Partnership to Deliver CE-Marked Heart Health Detection App to Fitbit Smartwatch Users in Europe

Fitbit users in Belgium, the Netherlands, Ireland and the United Kingdom can use FibriCheck to help detect heart rhythm irregularities like Atrial Fibrillation SAN FRANCISCO–(BUSINESS WIRE)–Fitbit (NYSE:FIT) and FibriCheck, an innovative health screening and monitoring app, today announced a partnership enabling users in Belgium, the Netherlands, Ireland and the UK to […]

FDA Awards AnaBios Grant to Further Develop Preclinical Assay Using Human Primary Cardiomyocytes

SAN DIEGO, Sept. 17, 2019 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has named AnaBios the recipient of a grant to further develop its unique drug discovery platform utilizing muscle cells from the human heart (cardiomyocytes).  Funds from the grant will be used to develop a preclinical biomarker to identify the […]

CorWave Presented First Successful In Vivo 60-Day Study on Its Innovative LVAD Cardiac Support Device

CLICHY, France–(BUSINESS WIRE)–CorWave announced that it successfully completed its first 60-day preclinical study to evaluate its Left Ventricular Assist Device (LVAD). The results were presented at the 46th Annual Conference of the European Society for Artificial Organs (ESAO) in Hannover. Trevor Snyder, PhD, Senior Director, Translational and Clinical Research at CorWave, […]

Ablacon Announces Release of New and Improved Ablamap Technology Under Existing CE Mark

MENLO PARK, Calif., Sept. 10, 2019 /PRNewswire/ — Ablacon, Inc. (www.ablacon.com), an Ajax Health-funded company, announced today the release of an updated version of its Ablamap technology under the company’s existing CE Mark.  The new update includes an enhanced physician experience and user interface, along with significantly faster processing times leading to improved […]